PFA
AQST icon

Pure Financial Advisors’s Aquestive Therapeutics AQST Stock Holding History

Pure Financial Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.1K Sell
20,222
-1,728
-8% -$7.27K ﹤0.01% 629
2026
Q1 		$91.1K Buy
+21,950
New +$89.1K ﹤0.01% 563

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Pure Financial Advisors's AQST Position: Q2 2026 in Review

Pure Financial Advisors reduced its Aquestive Therapeutics (AQST) stake by 7.9% in Q2 2026, selling an estimated $7.27K and leaving 20,222 shares worth $84.1K. The position accounts for ﹤0.01% of the portfolio, ranked #629.

Pure Financial Advisors first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. The position peaked at $91.1K in Q1 2026. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Pure Financial Advisors held 20,222 shares of Aquestive Therapeutics worth $84.1K as of Q2 2026.
  • Pure Financial Advisors sold 1,728 Aquestive Therapeutics shares in Q2 2026, an estimated $7.27K.
  • Aquestive Therapeutics made up ﹤0.01% of Pure Financial Advisors's portfolio in Q2 2026, its #629 holding.
  • Pure Financial Advisors first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Pure Financial Advisors's Aquestive Therapeutics position peaked at $91.1K in Q1 2026.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Pure Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.